An audit of patients who have received Imiquimod cream 5% for the treatment of anogenital warts

International Journal of STD and AIDS

Volumn 11, Issue 4, 2000, Pages 268-270

  Maitland, J E ^a   R, Maw ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Audit; Imiquimod cream 5

Indexed keywords

IMIQUIMOD; PODOPHYLLIN;

ADULT; ANUS DISEASE; ARTICLE; CREAM; DRUG EFFICACY; FEMALE; GENITAL SYSTEM DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VERRUCA VULGARIS;

ADOLESCENT; ADULT; AMINOQUINOLINES; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0034022617     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001915697     Document Type: Article

References (4)

1. 1 Edwards L, Ferenczy A, Eron L, and the HPV Study Group. Self-administered topical 5% Imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30
2. 2 K Beutner, J Geisse. Imiquimod - an immune response modifier for the treatment of anogenital warts. Today's Therapeutic Trends 1997;15:165-78
3. 3 Testerman T, Gerster J, Imbertson L, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leucocyte Biol 1995;58:365-72
4. 4 Tyring S, Arany I, Stanley M, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5